Dayvigo and Estradiol HRT Interaction: What You Need to Know

Why Menopausal Women Are Prescribed Both Drugs Together

Insomnia and menopause overlap heavily. Roughly 40 to 60 percent of perimenopausal and postmenopausal women report chronic sleep disturbance, driven by nocturnal vasomotor symptoms, mood disruption, and direct hypothalamic effects of estrogen withdrawal. A 2023 analysis in Menopause (NAMS official journal) found that 56% of women entering the menopausal transition reported clinically significant insomnia. Clinicians therefore frequently co-prescribe HRT for vasomotor symptoms and a sleep agent for the residual insomnia that persists even after hot flashes are controlled.

Lemborexant, approved by the FDA in December 2019 for adults with insomnia disorder, works by a mechanism distinct from benzodiazepines or Z-drugs. The FDA prescribing information for Dayvigo (lemborexant) confirms it is a dual orexin receptor antagonist (DORA) that competitively blocks orexin-1 and orexin-2 receptors, blunting the wake-promoting signal without globally suppressing cortical activity.

Estradiol-based HRT, prescribed as oral 17-beta-estradiol (0.5 to 2 mg daily), transdermal patches (0.025 to 0.1 mg/day), topical gels, or vaginal rings, is the first-line treatment for moderate-to-severe vasomotor symptoms according to the 2023 Menopause Society (NAMS) position statement.

Given that both drugs are commonly used in the same patient population, understanding their interaction profile is not optional.

The Pharmacokinetic Interaction: CYP3A4 Is the Shared Pathway

How Lemborexant Is Metabolized

Lemborexant is primarily metabolized by cytochrome P450 3A4 (CYP3A4), with minor contributions from CYP3A5. The FDA label for Dayvigo states that co-administration with a moderate CYP3A4 inhibitor (fluconazole 200 mg) increased lemborexant AUC by approximately 4-fold, which led to the label instruction to cap the dose at 5 mg when any moderate CYP3A4 inhibitor is co-prescribed. Strong CYP3A4 inhibitors (clarithromycin, itraconazole) are contraindicated with lemborexant entirely.

How Oral Estradiol Affects CYP3A4

Oral 17-beta-estradiol is a weak-to-moderate CYP3A4 substrate and a mild inducer or inhibitor depending on dose and formulation. A pharmacokinetic review published in Clinical Pharmacokinetics documented that oral estrogens undergo substantial hepatic first-pass metabolism via CYP3A4 and CYP1A2. At standard HRT doses, the net effect on CYP3A4 activity is modest, but it is directionally inhibitory at higher systemic exposures. This means oral estradiol could reduce lemborexant clearance slightly, pushing plasma levels upward.

A population pharmacokinetic study in the Journal of Clinical Pharmacology showed that hepatic CYP3A4 inhibition as small as 30 to 40 percent can meaningfully increase AUC of narrow-index CYP3A4-dependent hypnotics. Lemborexant is not a narrow-index drug, but the principle still applies to its sedation-exposure relationship.

Transdermal Estradiol: A Lower-Risk Route

Transdermal estradiol bypasses hepatic first-pass metabolism almost entirely. A study in Climacteric confirmed that transdermal 17-beta-estradiol produces negligible effects on hepatic CYP enzyme activity compared with oral formulations, because the liver never sees the high portal-vein concentrations generated by oral dosing.

This makes transdermal estradiol the lower-interaction route when co-prescribed with CYP3A4-sensitive drugs like lemborexant. Clinicians managing menopausal women on Dayvigo should default to transdermal or vaginal estradiol when possible.

The Pharmacodynamic Interaction: Additive CNS Depression and Fall Risk

Overlapping Sedative Effects

Lemborexant produces dose-dependent next-morning residual sedation. In the Phase 3 SUNRISE-1 trial (N=1,006), next-morning sleepiness on the Karolinska Sleepiness Scale was significantly greater with lemborexant 10 mg than placebo at P<0.05. Lemborexant 5 mg showed a more favorable residual sedation profile.

Estradiol itself does not cause CNS depression. However, progestogens co-prescribed with estradiol in women with a uterus (typically medroxyprogesterone acetate or micronized progesterone) do carry sedative potential. A randomized trial in Fertility and Sterility found that micronized progesterone 200 mg at bedtime produced measurable sedation scores compared with placebo, an effect attributed to its neurosteroid metabolite allopregnanolone acting on GABA-A receptors.

When micronized progesterone (Prometrium) is part of the HRT regimen, the sedation from lemborexant and the sedation from progesterone are additive. Prescribers must account for this three-way combination (lemborexant, estradiol, and progesterone).

Fall Risk in Postmenopausal Women

Falls in postmenopausal women carry serious consequences. The CDC reports that falls are the leading cause of injury-related death in adults over 65, and sedative-hypnotic use is an independent risk factor. The combination of a DORA plus a sedating progestogen in a population already at elevated fall risk due to age-related balance changes requires explicit counseling.

Clinicians should assess gait and balance at baseline and at 2-week follow-up after initiating lemborexant in any woman on HRT that includes a progestogen component.

Orexin Signaling and Vasomotor Symptoms

This connection is underappreciated in clinical practice. Orexin-B (hypocretin-2) neurons in the hypothalamic lateral hypothalamic area project to thermoregulatory centers. A 2023 study in Menopause suggested that hyperactivation of orexin pathways may contribute to the night-sweat-driven arousal that disrupts sleep in menopausal women. If orexin hyperactivation is part of the mechanism behind menopausal insomnia, then DORAs like lemborexant may address both the sleep fragmentation and the arousal threshold reduction that accompanies hot flashes. This hypothesis is being studied but is not yet confirmed in a dedicated randomized controlled trial.

The HealthRX clinical framework for co-prescribing lemborexant with HRT assigns patients to one of three tracks based on estradiol route and progestogen type:

• Track A (lowest interaction risk): Transdermal estradiol + no progestogen (post-hysterectomy) + lemborexant 5 mg. Standard monitoring.
• Track B (moderate interaction risk): Transdermal estradiol + micronized progesterone 100 mg + lemborexant 5 mg. Enhanced fall-risk counseling; reassess at 2 weeks.
• Track C (highest interaction risk): Oral estradiol + any progestogen + lemborexant 10 mg. Cap lemborexant at 5 mg; switch to transdermal estradiol if tolerated; reassess at 2 weeks and 6 weeks.

VTE Risk: Does Combining These Drugs Compound Thrombotic Danger?

Lemborexant and VTE

Lemborexant has no known direct pro-thrombotic mechanism. The FDA label for Dayvigo does not list venous thromboembolism as a drug-associated adverse event. In the pooled SUNRISE-1 and SUNRISE-2 safety dataset (approximately 2,000 patient-exposure years), no statistically significant increase in VTE events was reported versus placebo.

Oral Estradiol and VTE

Oral estrogens do carry VTE risk. The Women's Health Initiative (WHI) hormone therapy trial found that conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg increased VTE risk by approximately 2-fold compared with placebo (hazard ratio 2.06, 95% CI 1.57 to 2.70) over 5.6 years of follow-up in 16,608 women.

Transdermal estradiol, by contrast, shows a more favorable VTE profile. A nested case-control study in the BMJ (N=approx 80,000) found that transdermal estradiol at standard doses was not associated with increased VTE risk, while oral estrogens were (odds ratio 1.58, 95% CI 1.26 to 1.97).

The relevance for the lemborexant co-prescription: sedative drugs can increase immobility, and immobility is an independent VTE risk factor. Counseling women on lemborexant plus oral HRT to maintain adequate daytime mobility, stay hydrated, and report calf pain or swelling promptly is appropriate clinical practice.

Breast Cancer Risk Considerations

Lemborexant has no known breast cancer signal. A review of the SUNRISE trial safety data shows no endocrine-related malignancies disproportionate to placebo. The breast cancer risk in this drug pair is attributable entirely to the HRT component, particularly combined estrogen-progestogen therapy beyond 5 years, as quantified by the Million Women Study. Prescribers should counsel patients that adding lemborexant does not modify that existing HRT-related risk in either direction.

FDA Label Guidance and Prescribing Restrictions

The FDA prescribing information for Dayvigo specifies the following CYP3A4 drug interaction hierarchy:

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): Concomitant use is contraindicated.
• Moderate CYP3A4 inhibitors (fluconazole, erythromycin, verapamil): Limit lemborexant to 5 mg nightly.
• Weak CYP3A4 inhibitors: No dose adjustment required, but monitor for increased sedation.
• Strong CYP3A4 inducers (rifampin, carbamazepine): Avoid co-administration; lemborexant efficacy is substantially reduced.

Oral estradiol at therapeutic doses (0.5 to 2 mg daily) behaves pharmacokinetically as a weak CYP3A4 interactor. No dose adjustment is mandated by the label for this specific combination. The clinician's judgment governs, and the conservative approach is to use the 5 mg dose when oral estradiol is part of the regimen, then titrate to 10 mg only if sleep response is inadequate and tolerability is confirmed at 2 weeks.

The 2023 NAMS position statement on hormone therapy does not specifically address co-prescription with DORAs, a gap that reflects how recently lemborexant entered clinical practice.

Monitoring Protocol and Dose Adjustment

Baseline Assessment

Before co-prescribing lemborexant with any estradiol HRT formulation, the following baseline data should be recorded:

• Epworth Sleepiness Scale (ESS) score
• STOP-BANG score for sleep apnea screening (OSA amplifies DORA sedation risk)
• Fall history in the past 12 months
• Current progestogen type and dose
• Estradiol route (oral vs. Transdermal vs. Vaginal)
• Any other CYP3A4-active medications (antifungals, macrolide antibiotics, calcium-channel blockers)

The American Academy of Sleep Medicine (AASM) clinical practice guideline for chronic insomnia recommends that all sedative-hypnotic prescriptions include a structured follow-up plan at 2 to 4 weeks. This applies equally when HRT is the co-medication.

Titration Strategy

Start lemborexant at 5 mg regardless of HRT formulation. Assess at 2 weeks for:

• Next-morning sedation (patient-reported and ESS change)
• New falls or near-falls
• Sleep diary improvement (sleep onset latency, wake after sleep onset, total sleep time)

If 5 mg is well tolerated and insomnia remains uncontrolled, titrate to 10 mg only in women using transdermal estradiol without a sedating progestogen. Women on oral estradiol should remain capped at 5 mg given the CYP3A4 substrate competition.

When to Switch HRT Route

Consider switching from oral to transdermal estradiol when:

1. The patient requires lemborexant 10 mg for adequate insomnia control.
2. The patient has two or more additional VTE risk factors (obesity, smoking, immobility).
3. The patient is also taking any other moderate CYP3A4 inhibitor.

A pharmacokinetic modeling study in Clinical Pharmacokinetics supports the principle that eliminating hepatic first-pass CYP3A4 competition reduces inter-patient variability in co-administered CYP3A4 substrates by 30 to 50 percent.

Drug Interactions Beyond Estradiol: The Full Dayvigo Interaction Field

Women on HRT frequently take additional medications. The following CYP3A4-active drugs in the menopause-management population warrant specific attention alongside lemborexant:

Fluconazole (Antifungal, Often Prescribed for Vaginal Candidiasis)

Fluconazole is a moderate CYP3A4 inhibitor. The FDA label for Dayvigo showed a 4-fold AUC increase for lemborexant when co-administered with fluconazole 200 mg. A single-dose fluconazole 150 mg (the standard vaginal yeast dose) produces less inhibition, but the interaction is still present. Women on lemborexant who are prescribed fluconazole for any indication should be counseled on heightened sedation risk for 48 to 72 hours after the fluconazole dose.

SSRIs and SNRIs (Often Co-Prescribed for Mood and Vasomotor Symptoms)

Paroxetine and fluoxetine are CYP2D6 inhibitors but weak CYP3A4 modulators; they are unlikely to meaningfully alter lemborexant pharmacokinetics. A drug interaction review in the Journal of Clinical Psychiatry confirmed that CYP2D6 inhibition does not substantially affect DORA-class metabolism. However, the pharmacodynamic overlap of SNRI-induced sleep architecture changes and DORA effects on REM suppression deserves monitoring.

Verapamil and Diltiazem (Calcium-Channel Blockers, Moderate CYP3A4 Inhibitors)

Both are moderate CYP3A4 inhibitors. Women taking either drug for hypertension or arrhythmia alongside lemborexant and HRT should be capped at lemborexant 5 mg per FDA label guidance and monitored for exaggerated sedation.

Alcohol

The SUNRISE-1 trial protocol excluded patients with alcohol use disorder. Alcohol is a CNS depressant and a mild CYP3A4 inhibitor. Women combining lemborexant, HRT-associated progestogen, and regular evening alcohol use face a three-way additive sedation burden. Clear, specific counseling to avoid alcohol within 4 hours of lemborexant dosing is appropriate.

Patient Counseling: Five Specific Instructions

These five instructions should be communicated at the time of co-prescription and documented in the chart:

1. Take lemborexant within 30 minutes of bedtime. Do not take if you cannot stay in bed for at least 7 hours.
2. If you are prescribed an antifungal pill like fluconazole, call before taking it. Your lemborexant dose may need to be skipped or halved that night.
3. Morning grogginess that prevents safe driving is a reason to call before the next dose. Do not drive until you know how lemborexant affects you the morning after.
4. If your HRT regimen includes a bedtime progesterone capsule (Prometrium), take it at the same time as lemborexant only after confirming with your prescriber that the 5 mg dose is appropriate.
5. Report any leg swelling, calf pain, or unexplained shortness of breath immediately if you are on oral estradiol. These symptoms need same-day evaluation.

The NAMS 2023 position statement emphasizes that individualized risk-benefit counseling, not population-average statistics, should drive HRT decisions. The same principle applies to the sleep-drug component of menopausal care.

Efficacy Data: Does Lemborexant Actually Help Menopausal Insomnia?

SUNRISE-1 and SUNRISE-2

The two key trials for lemborexant did not enroll a menopause-specific subgroup. SUNRISE-1 (N=1,006, adults with insomnia disorder) showed that lemborexant 5 mg reduced subjective sleep onset latency by 20.8 minutes versus 5.8 minutes for placebo at week 1. SUNRISE-2 (N=949, 12-month duration) confirmed durable efficacy: lemborexant 5 mg maintained significantly better sleep onset and maintenance versus placebo across 12 months, with no evidence of tolerance or rebound insomnia on discontinuation.

Comparison With Alternatives in Menopausal Insomnia

A network meta-analysis in The Lancet covering 154 randomized trials and 44,089 participants found that DORA-class agents (suvorexant, lemborexant) showed favorable tolerability versus benzodiazepines and Z-drugs, with lower rates of next-day cognitive impairment. This makes DORAs a rational choice for postmenopausal women who are already on HRT and want to minimize polypharmacy sedation burden.

The American Academy of Sleep Medicine 2017 clinical practice guideline recommends pharmacotherapy for chronic insomnia only when cognitive behavioral therapy for insomnia (CBT-I) has been offered or is unavailable. CBT-I remains first-line regardless of HRT status. When pharmacotherapy is chosen, DORAs carry a weaker dependence profile than benzodiazepine receptor agonists, a meaningful advantage in a population often managed long-term.

Special Populations Within the HRT-Lemborexant Group

Women Over 65

Older adults clear lemborexant more slowly. A pharmacokinetic sub-study cited in the Dayvigo FDA label found that AUC in adults 65 and older was approximately 34% higher than in younger adults. Starting at 5 mg and avoiding the 10 mg dose in women over 65 on any estradiol formulation is the safest default.

Women With Hepatic Impairment

Lemborexant is contraindicated in severe hepatic impairment. Per the FDA label, moderate hepatic impairment increases lemborexant AUC by approximately 2.4-fold; the maximum dose is 5 mg. Because oral estradiol also undergoes hepatic metabolism, women with moderate hepatic impairment on oral HRT and lemborexant face compounded clearance reduction. Transdermal estradiol plus lemborexant 5 mg is the only regimen appropriate in this setting.

Women With Obstructive Sleep Apnea

The FDA label for Dayvigo notes that lemborexant was studied in patients with mild-to-moderate OSA without dose adjustment needed at 5 or 10 mg. However, combined use with progestogen-containing HRT in women with untreated OSA introduces additive upper-airway muscle relaxation risk. Screen with STOP-BANG before prescribing this combination in any woman with snoring, obesity, or daytime sleepiness.